Christina Herder appointed CEO of Modus Therapeutics

Modus Therapeutics AB, a Karolinska Development (STO:KDEV) portfolio company focused on innovative treatments for patients with sickle-cell disease, announces that Christina Herder has been appointed as its new Chief Executive Officer.

Christina currently holds the role of Director of Corporate Development at Sobi. Prior to that, she had created and led the Portfolio Management function within R&D in Sobi and brings over 20 years of experience from pharmaceutical product development.

Christina has a Ph.D in Physical Chemistry from the Royal Institute of Technology in Stockholm and an MBA from Stockholm University.

Christina replaces Pirkko Sulila Tamsen who left Modus Therapeutics in June 2014 after almost three years with the company.

Christina says: “I am very excited to join Modus Therapeutics at this crucial time in the company’s history. We now look forward to the continued development of sevuparin”.